Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Optinose US Inc.
- Study ID
- NCT06850805
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- OPN-375 — DRUGOPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID
- Placebo — DRUGPlacebo solution administered via exhalation delivery system (EDS).
Study Details
This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with chronic rhinosinusitis without nasal polyps. The total planned number of subjects is approximately 84 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 1:1 ratio (OPN-375 186 µg:placebo). The study includes a PK sub-study, in which up 14 subjects will be enrolled to obtain 10 completers.
Key Dates
- Start date
- Jul 28, 2025
- Status verified
- Mar 2026
- Primary completion
- Mar 31, 2028
- Completion
- Oct 31, 2028
Study Design
- Enrollment
- 84 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Placebo BIDDouble-Blind Treatment Phase: Intranasal administration of matching placebo BID x 12 weeks
- Active Comparator: OPN-375 186 µg BIDDouble-Blind Treatment Phase: Intranasal administration of OPN-375 186 µg x 12 weeks
Primary Outcome Measure
Change from baseline to the end of Week 4 in the average instantaneous CSS (evaluation of symptom severity immediately preceding the time of scoring). [ Time Frame: 4 Weeks ]
Central Contacts
- Alissa Sirbu484-751-4926
- Amy Manley
Locations (21)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| San Tan Allergy & Asthma | Gilbert | Arizona | 85214 | - |
| Children's Hospital of Orange County | Orange | California | 92868 | Jay Bhatt, MD (PRINCIPAL_INVESTIGATOR) |
| DaVinci Research, LLC | Sacramento | California | 95661 | Randall Ow, MD (PRINCIPAL_INVESTIGATOR) |
| Breathe Clear Institute | Torrance | California | 90503 | Steven Davis, MD (PRINCIPAL_INVESTIGATOR) |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | Sarah Gitomer, MD (PRINCIPAL_INVESTIGATOR) |
| Colorado ENT & Allergy | Colorado Springs | Colorado | 80909 | Bryan Davis, MD (PRINCIPAL_INVESTIGATOR) |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30329 | Kenneth Kennedy, MD (PRINCIPAL_INVESTIGATOR) |
| Southern Illinois University School of Medicine | Springfield | Illinois | 62702 | Dana Crosby, MD (PRINCIPAL_INVESTIGATOR) |
| Kentuckiana ENT | Louisville | Kentucky | 40205 | Thomas Higgins, MD (PRINCIPAL_INVESTIGATOR) |
| Centers for Advanced ENT Care | Towson | Maryland | 21204 | Douglas Reh, MD (PRINCIPAL_INVESTIGATOR) |
| University of Missouri Medical Center | Columbia | Missouri | 65212 | Christine Franzese, MD (PRINCIPAL_INVESTIGATOR) |
| University of Rochester Medical Center | Rochester | New York | 14642 | Li-Xing Man, MD (PRINCIPAL_INVESTIGATOR) |
| Allergy, Asthma and Clinical Research Center | Oklahoma City | Oklahoma | 73120 | Martha Tarpay, MD (PRINCIPAL_INVESTIGATOR) |
| Vital Prospects Clinical Research Institute | Tulsa | Oklahoma | 74136 | Iftikhar Hussain, MD (PRINCIPAL_INVESTIGATOR) |
| Charleston ENT & Allergy | North Charleston | South Carolina | 29414 | Thomas Murphy, MD (PRINCIPAL_INVESTIGATOR) |
| Carolina ENT Clinic/CENTRI Inc. | Orangeburg | South Carolina | 29118 | John Ansley, MD (PRINCIPAL_INVESTIGATOR) |
| Orion Clinical Research | Austin | Texas | 78759 | William Howland, III, MD (PRINCIPAL_INVESTIGATOR) |
| Alamo ENT Associates | San Antonio | Texas | 78258 | Jeffrey Rosenbloom, MD (PRINCIPAL_INVESTIGATOR) |
| STAAMP Research | San Antonio | Texas | 78229 | Erika Gonzalez, MD (PRINCIPAL_INVESTIGATOR) |
| University of Utah | Salt Lake City | Utah | 84112 | Jill Jeffe, MD (PRINCIPAL_INVESTIGATOR) |
| EVMS at Old Dominion University | Norfolk | Virginia | 23507 | Kent Lam, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Gilbert, AZ
Related Studies
- 3D Printing to Improve Nasal Irrigation OutcomeRecruiting · Ohio State University · Columbus, Ohio